Are regulatory bottlenecks impacting your ROI? Then look no further than the 3rd Cell Therapy Analytical Development Summit Europe, returning to London this September. With Resolution Therapeutics, Johnson & Johnson, GSK and more confirmed to speak, this meeting will provide you with the tools needed to face cell therapy approval challenges head on. 💰 Understand the cost-saving benefits of ddPCR technology with GLP-SR Tiget. 💵 Craft cost-effective potency assays with Resolution Therapeutics. 📈 Streamline your regulatory compliance with Johnson & Johnson. Discover all our cutting-edge sessions here: https://ter.li/fg45ak With time ticking away until we return to London, grab your pass whilst our best possible prices are still available! Secure your £350 saving now: https://ter.li/pxyfzp
Hanson Wade Group’s Post
More Relevant Posts
-
𝐁𝐫𝐚𝐢𝐧𝐒𝐭𝐨𝐫𝐦 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐀𝐥𝐢𝐠𝐧𝐬 𝐰𝐢𝐭𝐡 𝐅𝐃𝐀 𝐨𝐧 𝐂𝐌𝐂 𝐀𝐬𝐩𝐞𝐜𝐭𝐬 𝐟𝐨𝐫 𝐍𝐮𝐫𝐎𝐰𝐧® 𝐏𝐡𝐚𝐬𝐞 𝟑𝐛 𝐓𝐫𝐢𝐚𝐥 BrainStorm Cell Therapeutics (NASDAQ: BCLI) Brainstorm Cell Therapeutics has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b trial for NurOwn®, its investigational therapy for ALS. This follows the positive momentum from April 2024, when the FDA granted BrainStorm a Special Protocol Assessment (SPA) agreement, providing clarity on the trial's design and endpoints. "This in-person Type C meeting with the FDA was crucial as we finalize preparations for our pivotal Phase 3b trial of NurOwn. We are very pleased with the outcome and are now aligned on resolving all previously outstanding CMC questions," said Chaim Lebovits Chaim Lebovits, President & CEO of BrainStorm. "We are committed to working closely with the FDA and are excited to move forward with the Phase 3b trial to address the unmet needs of ALS patients." #ALS #StemCellTherapy #ClinicalTrials #FDA #NurOwn #BrainStormCellTherapeutics #Biotech #NeurodegenerativeDiseases
To view or add a comment, sign in
-
-
📢Novo Nordisk Acquires Cardior Pharmaceuticals for €1025bn: Promising Breakthrough in Heart Failure Treatment 📢 Novo Nordisk is acquiring Cardior Pharmaceuticals for up to €1.025bn, including milestone payments. ✨ Cardior's lead compound CDR132L is currently in Phase II clinical development for heart failure treatment. ⚙️ Cardior uses a non-coding RNA inhibitor to target microRNA-132, a central regulator of pathological cardiac remodelling processes. 💡 Novo Nordisk plans to initiate a Phase II trial for CDR132L in a chronic heart failure population. #BioprocessUpdates #NovoNordisk #CardiorPharmaceuticals #acquisition #clinicaldevelopment #heartfailure #CDR132L #PhaseIItrial #noncodingRNAinhibitor #microRNA132 #cardiacremodeling #chronicheartfailure #pharmaceuticalindustry #milestonepayments #healthcare #researchanddevelopment ▷ Read the full article here: 📎 https://lnkd.in/dti4Bd_6
To view or add a comment, sign in
-
-
𝐛𝐢𝐨𝐒𝐞𝐞𝐝𝐢𝐧 𝐍𝐄𝐖 𝐜𝐨𝐥𝐮𝐦𝐧, 𝐭𝐨 𝐬𝐡𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐲𝐨𝐮 𝐭𝐡𝐞 𝐯𝐢𝐬𝐢𝐨𝐧 𝐚𝐧𝐝 𝐭𝐫𝐞𝐧𝐝 𝐨𝐧 𝐭𝐡𝐞 𝐛𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐦𝐚𝐫𝐤𝐞𝐭. 𝐓𝐢𝐭𝐥𝐞 𝐟𝐨𝐫 𝐭𝐨𝐝𝐚𝐲’𝐬 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: bioSeedin bioSeedin Facilitates Strategic Licensing Partnership Between Supercede Therapeutics Supercede Therapeutics, Inc. and Leading Research Institutions bioSeedin is proud to announce its pivotal role in brokering a strategic cross-border licensing deal between Supercede Therapeutics and premier research institutions with a total deal value of $100M USD. This landmark agreement marks a significant step in the development of innovative treatments for obesity, focusing on a unique mechanism that simultaneously increases lean muscle mass while reducing fat. For full article, please see the link: https://lnkd.in/grA983tw
To view or add a comment, sign in
-
-
🚀 Kicking off Day 2 of the 20th BioPharma Drug Discovery Nexus Conference with a bang! Join Mauro Mileni Founder and CEO, Abilita Therapeutics, Inc. as he unveils insights into 'Enabling the Discovery of Therapeutic Antibodies Targeting Challenging Membrane Proteins'. Don't miss out on this enlightening session! #BioPharma #DrugDiscovery #Innovation #Antibodies #Therapeutics #Membraneproteins #Epitopes #Conformational #Protiens #NexusConference #SanDiego #USconference #ScientificConference
To view or add a comment, sign in
-
-
The evolution of biologics 🧪 has been a game-changer for those who live with multiple sclerosis, offering hope and improved quality of life. In our latest blog post, we explore 🌎 how biologics work to treat MS and the different biologics available to MS patients.
To view or add a comment, sign in
-
https://lnkd.in/gaAKgDzW Key Insights: • As per the agreements, FUJIFILM Cellular Dynamics stands to gain specific development and regulatory milestone payments, along with royalties tied to products developed under the collaboration between the companies Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #fujifilm #autoimmune #inflammatory #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases | MedicoInsights
medicoinsights.com
To view or add a comment, sign in
-
Ready to revolutionise the storage of mRNA drugs 🤓
Pleased to announce our participation at the 3rd mRNA Based Therapeutics Summit in Berlin, January 24rd - 25th! Join Joris Lammens and Alain Segers at booth #3 to learn more about the thermostability of mRNA-based drugs. 💉 Don't miss our poster presentation on: “Continuous and controlled lyophilization as a strategy to increase shelf life of mRNA-LNPs”. 📃 Let's connect! Looking forward to meeting you at the conference. 🤝
To view or add a comment, sign in
-
-
Interested in learning more about icIEF fractionation followed by mass spec? We have a webinar next week, on June 20th, with Lan Li from Amgen and Amreen Jonas from Mersana Therapeutics. You can use the link below to register. I am very excited about this one! #MassSpec
Utilizing novel icIEF fractionation and mass spec for the charge characterization of biotherapeutics - Endpoints Webinars
webinars.endpts.com
To view or add a comment, sign in
-
Caring for patients by making tomorrow's medicines in partnership 🤝; an inter-disciplinary translator;🚶🏻✝️; 🚵♀️; Opinions are only mine😉
What's the state of the commercial R&D #antibodydrugconjugates space? The Antibody Society has just released its summary of the commercial antibody therapeutics pipeline that they carefully manually curate. Having reviewed it I've summarised over 400 ADCs and RITs that have been or are in commercial R&D up to Oct 2023. Key insight: It's a competitive space, around relatively few targets with a substantial risk of termination. It's exciting and competitive times for those of us driving #antibodydrugconjugates #scienceandtechnology #innovation #precisionmedicine #pharmacology to help transform patients' lives. The first three rows in the table correspond to the graphs in descending order.
To view or add a comment, sign in
-
-
Senior Conference Producer at Hanson Wade | First Class MSci Chemistry Graduate from Imperial College London
The hotly anticipated 2nd RNA Assay Development & Screening Summit returns to Boston, August 20-22, 2024, to revolutionize RNA-targeted drug discovery with robust assays and screens. Check out the Brand-New Event Guide here: https://ter.li/zuknlg Don’t miss your opportunity to see expert talks with industry leaders from AstraZeneca, Arrakis Therapeutics, Biogen, NextRNA Therapeutics, Accent Therapeutics, Inc. , Atavistik Bio and many more, at the industry's first and only conference dedicated to supporting in-house assay development and screening strategies for discovering selective RNA-targeting small molecules. #RNAtargeting #RNA #smallmolecules #drugdiscovery #assaydevelopment #assay #screening
To view or add a comment, sign in
-